Update: FDA now recommends prescribing naloxone and requires new labeling changes for opioids In its Drug Safety Communication from July 23, 2020, the Food and Drug Administration (FDA) has announced that it recommends that health care professionals consider prescribing naloxone to patients at increased risk of opioid overdose, including those taking benzodiazepines or other CNS […]
The FDA continues to warn practitioners that respiratory depression may occur in patients taking the drugs gabapentin or pregabalin, especially patients who are also predisposed to respiratory depression due to their concomitant use of other respiratory depressants, such as opioid analgesics, and other drugs that depress the central nervous system, such as benzodiazepines. Patients with
Gabapentinoids and Potential Respiratory Depression with Dental Drugs Read More »
With over 30 years’ experience as a pharmacist, dental educator and author, Tom Viola, R.Ph. has earned his reputation as the go-to specialist for delivering quality dental continuing education content through his informative, fun and engaging dental pharmacology presentations.
Copyright © 2024 Thomas A. Viola, R.Ph., C.C.P. Pharmacology Declassified. All Rights Reserved.
